NO20050216L - Steroidkonjugater samt fremstilling og anvendelse derav - Google Patents

Steroidkonjugater samt fremstilling og anvendelse derav

Info

Publication number
NO20050216L
NO20050216L NO20050216A NO20050216A NO20050216L NO 20050216 L NO20050216 L NO 20050216L NO 20050216 A NO20050216 A NO 20050216A NO 20050216 A NO20050216 A NO 20050216A NO 20050216 L NO20050216 L NO 20050216L
Authority
NO
Norway
Prior art keywords
conjugates
preparation
taxol
treatment
steroid conjugates
Prior art date
Application number
NO20050216A
Other languages
English (en)
Inventor
Elias Castanas
Original Assignee
Medexis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexis Sa filed Critical Medexis Sa
Publication of NO20050216L publication Critical patent/NO20050216L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Konjugater omfattende ett eller flere stereoider konjugert med ett eller flere pattedyrproteiner er beskrevet. Konjugatene er anvendelige for diagnose eller behandling av faste krefttyper og hematologiske sykdommer. Videre oppviser konjugatene en synergistisk virkning sammen med et cytoskjelettvirkende medikament så som Taxol( som tillater behandling av krefttyper som ellers ikke ville reagere på Taxol(.
NO20050216A 2002-07-16 2005-01-13 Steroidkonjugater samt fremstilling og anvendelse derav NO20050216L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR20020100335A GR1004274B (el) 2002-07-16 2002-07-16 Συμπλοκα στεροειδων ορμονων με πρωτεινες: νεες ουσιες για την ειδικη ανιχνευση και καταστροφη καρκινικων κυτταρων προερχομενων απο στερεους ογκους και αιματολογικες κακοηθειες
PCT/IB2003/002785 WO2004006966A1 (en) 2002-07-16 2003-07-14 Steroid conjugates, preparation thereof and the use thereof

Publications (1)

Publication Number Publication Date
NO20050216L true NO20050216L (no) 2005-04-14

Family

ID=29559909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050216A NO20050216L (no) 2002-07-16 2005-01-13 Steroidkonjugater samt fremstilling og anvendelse derav

Country Status (11)

Country Link
US (1) US7495115B2 (no)
EP (1) EP1523338A1 (no)
JP (1) JP2006507230A (no)
KR (1) KR20050040905A (no)
CN (1) CN1668339A (no)
GR (1) GR1004274B (no)
HR (1) HRP20050142A2 (no)
IL (1) IL165779A0 (no)
IS (1) IS7694A (no)
NO (1) NO20050216L (no)
WO (1) WO2004006966A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355081B2 (en) * 2002-04-17 2008-04-08 The University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
DE102004034008A1 (de) * 2004-07-14 2006-02-09 Rösner Research GmbH & Co.KG Verfahren zur Herstellung von Albumin-Corticoid-Konjugaten
GR1005808B (el) * 2006-11-27 2008-02-06 Bionature E.A. Limited Επιταση της δρασεως της ερυθροποιητινης με αγωνιστες των μεμβρανικων στεροειδων υποδοχεων
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
GB201015784D0 (en) 2010-09-20 2010-10-27 Bionature E A Ltd Anti-cancer compounds
CN107652344B (zh) * 2016-07-25 2020-09-25 深圳迈瑞生物医疗电子股份有限公司 化合物、缀合物、试剂盒及其在检测睾酮或其类似物中的用途
BR112020013492A2 (pt) * 2018-01-08 2020-12-08 Regeneron Pharmaceuticals, Inc. Esteroides e conjugados de anticorpo dos mesmos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56467A (en) * 1978-02-10 1982-04-30 Sin Hang Lee Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues
US4215102A (en) * 1979-01-05 1980-07-29 Lee Sin H Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues
NZ196126A (en) 1980-02-07 1985-05-31 Commw Scient Ind Res Org Increasing ovulation rate in female cattle
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5834213A (en) * 1991-05-02 1998-11-10 Baylor College Of Medicine Screening system and assay for identifying compounds that regulate steroid and orphan receptors mediation of DNA transcription
WO1993002691A1 (en) 1991-08-09 1993-02-18 Mount Sinai School Of Medicine Of The City University Of New York Steroid hormone drug delivery
US5248796A (en) * 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO1999061055A1 (en) * 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6380405B1 (en) * 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
EP1104667A1 (en) 1999-11-29 2001-06-06 The Procter & Gamble Company Disposable absorbant article having fecal management layer
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
IL154529A0 (en) * 2000-09-14 2003-09-17 Univ British Columbia Antisense insulin-like growth factor binding protein (igfep)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
US7199115B2 (en) * 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them

Also Published As

Publication number Publication date
KR20050040905A (ko) 2005-05-03
HRP20050142A2 (en) 2005-10-31
JP2006507230A (ja) 2006-03-02
WO2004006966A1 (en) 2004-01-22
GR1004274B (el) 2003-06-23
US20050245442A1 (en) 2005-11-03
EP1523338A1 (en) 2005-04-20
IS7694A (is) 2005-02-11
IL165779A0 (en) 2006-01-15
US7495115B2 (en) 2009-02-24
CN1668339A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
BR0310088A (pt) Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s)
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
ATE291097T1 (de) Expressionsprofile in adulten und fötalen organen
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BRPI0512146A (pt) métodos para o tratamento de uma infecção endobrÈnquica em um paciente, e de um paciente com fibrose cìstica, sofrendo de uma infecção endobrÈnquica
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
ECSP088203A (es) Dispersiones amorfas sólidas
BR112022011032A2 (pt) Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
TR200200619T2 (tr) İkame edilmiş fenoksiasetik asitler.
BR112022018766A2 (pt) Formulações de anticorpo de protofibrila anti-ass de concentração alta e métodos de uso das mesmas
CO2021013251A2 (es) Derivados de insulina sensibles a la glucosa
BR0311866A (pt) Composições de saponinas ou sapogeninas para terapia de câncer
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
EA200100568A1 (ru) Фармацевтические композиции в капсулах из гидроксипропилметилцеллюлозы
BRPI0611526A2 (pt) composição tópica contendo gelatina